ihacares.com
Jun 6, 2024, 14:04
Elie G. Dib: TAPUR study has been presented at the 2024 ASCO Annual Meeting!
Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital, posted on LinkedIn:
“Exciting News!
I’m thrilled to share that TAPUR study on the antitumor activity of Pertuzumab and Trastuzumab in advanced solid tumors with ERBB2/3 alterations has been presented at the 2024 ASCO Annual Meeting!
This research, conducted with the incredible team at Trinity Health MI (Ann Arbor) and other sites across the nation, shows promising results with a disease control rate of 57% and an objective response rate of 29%.
Onward to more advancements in cancer treatment!”
Additional information.
Source: Elie G. Dib/LinkedIn
Abby Gregory
Ajjai Shivaram Alva
Allison Paige Watson
American Society for Clinical Oncology
Ann Arbor
ASCO
ASCO24
cancer treatment
Carmen Julia Calfa
Deepti Behl
Elie G. Dib
Elizabeth Garrett-Mayer
ERBB2/3
Eugene Ahn
Evthokia Hobbs
Funda Meric-Bernstam
Kathleen J Yost
Mehmet Akce
Meredith McKean
Michael Rothe
Navid Hafez
Pam K. Mangat
pertuzumab
Ramya Thota
Richard L. Schilsky
Saint Joseph Mercy Hospital
Susan Halabi
TAPUR study
Timothy Lewis Cannon
trastuzumab
Trinity Health MI
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43